Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
Blood Cancer Discovery
|
October 18, 2021
Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
Malin Hultcrantz, Joshua Richter, Cara A Rosenbaum, et al.
Blood Cancer Discovery
|
October 15, 2021
COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
Malin Hultcrantz, Joshua Richter, Cara A Rosenbaum, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 9, 2020
An inflammatory cytokine signature helps predict COVID-19 severity and death
Diane Marie Del Valle, Seunghee Kim-Schulze, Huang Hsin-Hui, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2025
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Sundar Jagannath, Thomas G Martin, Yi Lin, et al.
Nature Medicine
|
August 26, 2020
An inflammatory cytokine signature predicts COVID-19 severity and survival
Diane Marie Del Valle, Seunghee Kim-Schulze, Hsin-Hui Huang, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 20, 2026
Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies
Paula Rodríguez-Otero, Jaime Gállego Pérez-Larraya, Yi Lin, et al.
Lancet (London, England)
|
June 27, 2021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesus G Berdeja, Deepu Madduri, Saad Z Usmani, et al.
Nature Medicine
|
April 20, 2026
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial
Omar Nadeem, David M Cordas Dos Santos, Sarah Nikiforow, et al.
Leukemia & Lymphoma
|
April 21, 2020
Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients
Sarah Goldman-Mazur, Artur Jurczyszyn, Jorge J Castillo, et al.
American Journal of Hematology
|
February 20, 2020
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma
Sarah Goldman-Mazur, Artur Jurczyszyn, Jorge J Castillo, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
Blood Cancer Discovery
|
October 18, 2021
Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
Malin Hultcrantz, Joshua Richter, Cara A Rosenbaum, et al.
Blood Cancer Discovery
|
October 15, 2021
COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
Malin Hultcrantz, Joshua Richter, Cara A Rosenbaum, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 9, 2020
An inflammatory cytokine signature helps predict COVID-19 severity and death
Diane Marie Del Valle, Seunghee Kim-Schulze, Huang Hsin-Hui, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2025
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Sundar Jagannath, Thomas G Martin, Yi Lin, et al.
Nature Medicine
|
August 26, 2020
An inflammatory cytokine signature predicts COVID-19 severity and survival
Diane Marie Del Valle, Seunghee Kim-Schulze, Hsin-Hui Huang, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 20, 2026
Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies
Paula Rodríguez-Otero, Jaime Gállego Pérez-Larraya, Yi Lin, et al.
Lancet (London, England)
|
June 27, 2021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesus G Berdeja, Deepu Madduri, Saad Z Usmani, et al.
Nature Medicine
|
April 20, 2026
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial
Omar Nadeem, David M Cordas Dos Santos, Sarah Nikiforow, et al.
Leukemia & Lymphoma
|
April 21, 2020
Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients
Sarah Goldman-Mazur, Artur Jurczyszyn, Jorge J Castillo, et al.
American Journal of Hematology
|
February 20, 2020
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma
Sarah Goldman-Mazur, Artur Jurczyszyn, Jorge J Castillo, et al.
Page
of 5